Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Co-g-C3N4 Nanozyme-Based Colorimetric Biosensor for miR-320a Detection in Thyroid-Associated Ophthalmopathy.

Created on 15 Jul 2026

Authors

Xiujin Liu, Gengneng Lai, Zongcheng Shu, Wei Li, Fang Ke

Published in

Journal of fluorescence. Jul 15, 2026. Epub Jul 15, 2026.

Abstract

Thyroid-associated ophthalmopathy (TAO) is a complex autoimmune inflammatory disease. There is an urgent clinical need for highly sensitive and minimally invasive biomarkers to enable early diagnosis and dynamic disease monitoring. Among them, miR-320a has been confirmed to be closely associated with oxidative stress regulation, fibroblast activation, and fibrosis progression. However, current detection methods, especially those based on real-time quantitative polymerase chain reaction (RT-qPCR), still suffer from cumbersome procedures, high instrumentation costs, and limited adaptability for rapid point-of-care diagnostics. To address this, we developed a nanozyme-assisted colorimetric biosensing platform integrating target-triggered probe hybridization with Co-g-C3N4, which exhibits enhanced peroxidase-like activity and stability. The method involves Co-g-C3N4 synthesis, probe-nanozyme interface construction, catalytic optimization, and colorimetric detection via TMB oxidation, validated in spiked serum and with smartphone readout. The platform achieves sensitive miR-320a detection down to picomole levels with excellent linearity and specificity. In spiked human serum analysis, it reliably quantifies endogenous miR-320a with strong recovery rates (94.6-108.9%). However, we acknowledge that direct clinical validation using confirmed TAO patient samples is required for full diagnostic implementation, and this represents a limitation of the current study. Generally speaking, this work provides a portable, cost-effective, amplification-free colorimetric nanozyme platform for miRNA detection, requiring only basic laboratory equipment, and holding significant promise for point-of-care precision diagnostics in autoimmune and fibrotic diseases.

PMID:
42455399
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement